SARS-Cov-2

The economic burden of long COVID may exceed $2 billion and reach nearly $31 billion when symptoms last between 1 and 3 years, and researchers say these numbers will likely continue to grow as COVID-19 cases increase.

SAN FRANCISCO — Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 within 3 days of that person developing symptoms, researchers reported.

SAN FRANCISCO — A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk for long COVID, according to study data.

Developing myalgic encephalomyelitis/chronic fatigue syndrome is significantly more likely after a case of COVID-19, an important connection for rheumatologists as they sort through symptoms and medical histories for a diagnosis, data show.

Children and adolescents with documented postacute COVID-19 syndrome experienced increased risk for gastrointestinal symptoms and disorders, according to a study published in JAMA Open Network.

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as previously thought, according to research published in JAMA.

In 5 years, COVID-19 has impacted nearly every aspect of life. Although tens of thousands of cases continue to occur each week, the world’s top public health agencies have considered the pandemic phase of COVID-19 to be over for years.

SARS-CoV-2 infection was associated with more rapid coronary plaque progression and significantly increased risk for adverse outcomes related to target lesion failure, such as heart attack and death, researchers reported.

The vast majority of people in a study with long COVID had experienced multiple SARS-CoV-2 infections over the course of a 4-year period, researchers reported.

Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome, an NIH-funded study showed.